<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453918</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-381</org_study_id>
    <secondary_id>2017-A01955-48</secondary_id>
    <nct_id>NCT03453918</nct_id>
  </id_info>
  <brief_title>Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.</brief_title>
  <acronym>POLYFER</acronym>
  <official_title>Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysmetabolic iron overload syndrome and genetic hemochromatosis are frequent causes of iron
      overload. Polyphenols are efficient iron-chelators. Investigator hypothesize that polyphenol
      supplementation can reduce iron absorption in iron overload disease. Iron absorption can be
      studied by the area-under-the-curve of serum iron after iron oral loading. The primary
      outcome is the decrease of post-prandial serum iron after rich-iron meal, due to polyphenol
      supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron overload diseases are highly prevalent. Dysmetabolic iron overload syndrome involves 15%
      of men with metabolic syndrome X. Genetic hemochromatosis is the most common genetic disease
      in Northern Europe. Both are due to a lack of regulation in iron absorption. To date, there
      is no nutritional study for those patients.

      Polyphenols, particularly flavanols, have shown as good iron-chelating abilities as
      pharmacological chelators. However, no human study in iron-overload disease have been so far
      conducted.

      The aim of POLYFER-study is to demonstrate that oral polyphenol intake reduces iron
      absorption in patients with genetic or metabolic iron-overload diseases.

      POLYFER is a cross-over randomized controlled trial comparing the effect of polyphenol
      supplementation versus placebo on iron absorption after loading dose of iron given through a
      rich-iron meal. Iron absorption will be studied by the area under the curve of serum iron
      after the meal. Serum iron will be collected after the meal à 0 minute, 30 minutes, 1 hour, 2
      hours, 3 hours et 4 hours.

      Because of the nycthemeral variations of serum iron, it is essential to obtain a collection
      of serum iron data in the basal state (after fasting), allowing the calculation for each
      subject of a &quot;relative&quot; AUC after iron-rich meal with placebo and after iron-rich meal with
      polyphenols. The endpoint will be the difference between &quot;relative&quot; AUC after meal rich in
      iron alone and after polyphenols.

      In order to improve the underlying mechanism of atherosclerosis which is highly prevalent in
      those diseases, we will conduct an ancillary study. Recent studies showed interesting results
      linking some oxylipins levels and inflammation. Investigator will study basal oxylipin level
      and post-prandial oxylipin level by lipidomic analysis in both diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of post-prandial iron absorption after dietary polyphenol supplementation</measure>
    <time_frame>at day 3</time_frame>
    <description>decrease of intestinal iron absorption after standardized oral loading dose through rich-iron meal, expressed by area-under-the-curve of serum iron, due to concomitant administration of a single dose of dietary polyphenos (nutrient complement) versus placebo administration. This outcome is a quantitative variable, treated and analysed as such.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-prandial changes of circulating oxylipin in iron overload diseases after iron-rich meal and effects of polyphenols supplementation</measure>
    <time_frame>at day 1 (fasting versus 3 hours after rich-iron meal, versus 3 hours after rich-iron meal with polyphenol supplementation)</time_frame>
    <description>comparison of oxylipin levels, through lipidomic analyses by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of oxylipin levels between DIOS, genetic hemochromatosis and healthy subjects after 6 hours of fasting.</measure>
    <time_frame>at baseline</time_frame>
    <description>comparison of oxylipin levels, through lipidomic analyses by spectrophotometry. Healthy subjects datas comes from a previous study (MEPHISTO).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dysmetabolic Iron Overload Syndrome</condition>
  <condition>Genetic Hemochromatosis</condition>
  <condition>Iron Absorption</condition>
  <condition>Polyphenols</condition>
  <arm_group>
    <arm_group_label>Polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>polyphenols</intervention_name>
    <description>After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).
During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.
The diet consists of :
Starter: duck gizzard salad.
Main course: black pudding and pasta.
French cheese.
Fruits: kiwi fruit.
This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.
At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.</description>
    <arm_group_label>Polyphenols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).
During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.
The diet consists of :
Starter: duck gizzard salad.
Main course: black pudding and pasta.
French cheese.
Fruits: kiwi fruit.
This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.
At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old and over

          -  Written consent.

          -  For DIOS Group : at least one criteria of the metabolic syndrome as defined by the
             International Diabetes Federation, associated with hepatic iron overload measured by
             MRI (at least 50 µmol/g) or by hepatic biopsy.

          -  For Genetic Haemochromatosis type 1 Group: homozygosity mutation C282Y in HFE gene ;
             patients undergoing therapeutic phlebotomies.

        Exclusion Criteria:

          -  Persons under guardianship

          -  Body-weight less than 45 kg

          -  Hemoglobin less than 9 g/dL.

          -  Intestinal malabsorption of any cause

          -  Current use or previous use during the last 2 months of iron supplement.

          -  Current use or previous use during the last 2 months of treatment interacting with
             iron absorption (increasing like C vitamin or decreasing like iron chelators)

          -  Other causes of hyperferritinemia : chronic inflammatory syndrome, porphyria,
             hyperferritinemia-cataract-syndrome, chronic alcohol consumption, chronic hemolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc RUIVARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>0473751195</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>0473751195</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Marc RUIVARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian DUALE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.purextract.fr/produits/oligopin.html</url>
  </link>
  <reference>
    <citation>Brissot P, Ropert M, Le Lan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012 Mar;1820(3):403-10. doi: 10.1016/j.bbagen.2011.07.014. Epub 2011 Aug 9. Review.</citation>
    <PMID>21855608</PMID>
  </reference>
  <reference>
    <citation>Gutteridge JM, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci (Lond). 1985 Apr;68(4):463-7.</citation>
    <PMID>2578915</PMID>
  </reference>
  <reference>
    <citation>Brown KE, Dennery PA, Ridnour LA, Fimmel CJ, Kladney RD, Brunt EM, Spitz DR. Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int. 2003 Aug;23(4):232-42.</citation>
    <PMID>12895262</PMID>
  </reference>
  <reference>
    <citation>Ganz T. Systemic iron homeostasis. Physiol Rev. 2013 Oct;93(4):1721-41. doi: 10.1152/physrev.00008.2013. Review.</citation>
    <PMID>24137020</PMID>
  </reference>
  <reference>
    <citation>Jouanolle AM, Fergelot P, Gandon G, Yaouanq J, Le Gall JY, David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997 Oct;100(5-6):544-7.</citation>
    <PMID>9341868</PMID>
  </reference>
  <reference>
    <citation>Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P; Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005 Apr 28;352(17):1769-78.</citation>
    <PMID>15858186</PMID>
  </reference>
  <reference>
    <citation>Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 Jan 17;358(3):221-30. doi: 10.1056/NEJMoa073286.</citation>
    <PMID>18199861</PMID>
  </reference>
  <reference>
    <citation>Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999 Nov;117(5):1155-63.</citation>
    <PMID>10535879</PMID>
  </reference>
  <reference>
    <citation>Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, Shiota G. High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism. 2013 Jan;62(1):62-9. doi: 10.1016/j.metabol.2012.06.008. Epub 2012 Jul 30.</citation>
    <PMID>22854109</PMID>
  </reference>
  <reference>
    <citation>Le Guenno G, Chanséaume E, Ruivard M, Morio B, Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract. 2007 Sep;77(3):363-70. Epub 2007 Mar 9.</citation>
    <PMID>17350134</PMID>
  </reference>
  <reference>
    <citation>Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, Nemeth E, Rambeau M, Mazur A, Gerbaud L, Tournilhac V, Abergel A, Philippe P, Deugnier Y, Coudray C. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol. 2009 Jun;50(6):1219-25. doi: 10.1016/j.jhep.2009.01.029. Epub 2009 Apr 5.</citation>
    <PMID>19398238</PMID>
  </reference>
  <reference>
    <citation>Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 Apr;37(7):720-9. doi: 10.1111/apt.12255. Epub 2013 Feb 26.</citation>
    <PMID>23441892</PMID>
  </reference>
  <reference>
    <citation>Assi TB, Baz E. Current applications of therapeutic phlebotomy. Blood Transfus. 2014 Jan;12 Suppl 1:s75-83. doi: 10.2450/2013.0299-12. Epub 2013 Oct 3. Review.</citation>
    <PMID>24120605</PMID>
  </reference>
  <reference>
    <citation>Brune M, Rossander L, Hallberg L. Iron absorption and phenolic compounds: importance of different phenolic structures. Eur J Clin Nutr. 1989 Aug;43(8):547-57.</citation>
    <PMID>2598894</PMID>
  </reference>
  <reference>
    <citation>Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr. 1999 Apr;81(4):289-95.</citation>
    <PMID>10999016</PMID>
  </reference>
  <reference>
    <citation>Cook JD, Reddy MB, Hurrell RF. The effect of red and white wines on nonheme-iron absorption in humans. Am J Clin Nutr. 1995 Apr;61(4):800-4.</citation>
    <PMID>7702022</PMID>
  </reference>
  <reference>
    <citation>Tuntawiroon M, Sritongkul N, Brune M, Rossander-Hultén L, Pleehachinda R, Suwanik R, Hallberg L. Dose-dependent inhibitory effect of phenolic compounds in foods on nonheme-iron absorption in men. Am J Clin Nutr. 1991 Feb;53(2):554-7.</citation>
    <PMID>1989426</PMID>
  </reference>
  <reference>
    <citation>Tako E, Beebe SE, Reed S, Hart JJ, Glahn RP. Polyphenolic compounds appear to limit the nutritional benefit of biofortified higher iron black bean (Phaseolus vulgaris L.). Nutr J. 2014 Mar 26;13:28. doi: 10.1186/1475-2891-13-28.</citation>
    <PMID>24669764</PMID>
  </reference>
  <reference>
    <citation>Tako E, Reed SM, Budiman J, Hart JJ, Glahn RP. Higher iron pearl millet (Pennisetum glaucum L.) provides more absorbable iron that is limited by increased polyphenolic content. Nutr J. 2015 Jan 23;14:11. doi: 10.1186/1475-2891-14-11.</citation>
    <PMID>25614193</PMID>
  </reference>
  <reference>
    <citation>Sjödin P, Wallin H, Alexander J, Jägerstad M. Disposition and metabolism of the food mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in rats. Carcinogenesis. 1989 Jul;10(7):1269-75.</citation>
    <PMID>2661045</PMID>
  </reference>
  <reference>
    <citation>Ríos-Hoyo A, Cortés MJ, Ríos-Ontiveros H, Meaney E, Ceballos G, Gutiérrez-Salmeán G. Obesity, Metabolic Syndrome, and Dietary Therapeutical Approaches with a Special Focus on Nutraceuticals (Polyphenols): A Mini-Review. Int J Vitam Nutr Res. 2014;84(3-4):113-23. doi: 10.1024/0300-9831/a000198. Review.</citation>
    <PMID>26098475</PMID>
  </reference>
  <reference>
    <citation>Moukette BM, Pieme CA, Njimou JR, Biapa CP, Marco B, Ngogang JY. In vitro antioxidant properties, free radicals scavenging activities of extracts and polyphenol composition of a non-timber forest product used as spice: Monodora myristica. Biol Res. 2015 Mar 14;48:15. doi: 10.1186/s40659-015-0003-1.</citation>
    <PMID>25885269</PMID>
  </reference>
  <reference>
    <citation>Tondeur MC, Schauer CS, Christofides AL, Asante KP, Newton S, Serfass RE, Zlotkin SH. Determination of iron absorption from intrinsically labeled microencapsulated ferrous fumarate (sprinkles) in infants with different iron and hematologic status by using a dual-stable-isotope method. Am J Clin Nutr. 2004 Nov;80(5):1436-44.</citation>
    <PMID>15531698</PMID>
  </reference>
  <reference>
    <citation>Ruivard M, Feillet-Coudray C, Rambeau M, Gerbaud L, Mazur A, Rayssiguier Y, Philippe P, Coudray C. Effect of daily versus twice weekly long-term iron supplementation on iron absorption and status in iron-deficient women: a stable isotope study. Clin Biochem. 2006 Jul;39(7):700-7. Epub 2006 Apr 5.</citation>
    <PMID>16603147</PMID>
  </reference>
  <reference>
    <citation>Hoppe M, Hulthén L, Hallberg L. Serum iron concentration as a tool to measure relative iron absorption from elemental iron powders in man. Scand J Clin Lab Invest. 2003;63(7-8):489-96.</citation>
    <PMID>14743958</PMID>
  </reference>
  <reference>
    <citation>Andersen SL, Gyrup C, Handberg A, Nielsen GL. Oral iron absorption test should not be performed with iron drops containing ferric iron. Dan Med J. 2015 Aug;62(8):A5116.</citation>
    <PMID>26239588</PMID>
  </reference>
  <reference>
    <citation>Hoppe M, Hulthén L. Validation of the clinical approach of using the induced serum iron increase after 1h as a measure of iron absorption. Clin Nutr. 2006 Feb;25(1):163-5. Epub 2005 Nov 22.</citation>
    <PMID>16307831</PMID>
  </reference>
  <reference>
    <citation>Kloepfer K, Schmid P, Wuillemin WA, Rüfer A. Reference values for oral iron absorption of bivalent iron in healthy volunteers. Swiss Med Wkly. 2015 Jan 22;145:w14063. doi: 10.4414/smw.2015.14063. eCollection 2015.</citation>
    <PMID>25612208</PMID>
  </reference>
  <reference>
    <citation>Kobune M, Miyanishi K, Takada K, Kawano Y, Nagashima H, Kikuchi S, Murase K, Iyama S, Sato T, Sato Y, Takimoto R, Kato J. Establishment of a simple test for iron absorption from the gastrointestinal tract. Int J Hematol. 2011 Jun;93(6):715-719. doi: 10.1007/s12185-011-0878-8. Epub 2011 Jun 1.</citation>
    <PMID>21626456</PMID>
  </reference>
  <reference>
    <citation>Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012;7(11):e48852. doi: 10.1371/journal.pone.0048852. Epub 2012 Nov 8.</citation>
    <PMID>23144998</PMID>
  </reference>
  <reference>
    <citation>Rametta R, Dongiovanni P, Pelusi S, Francione P, Iuculano F, Borroni V, Fatta E, Castagna A, Girelli D, Fargion S, Valenti L. Hepcidin resistance in dysmetabolic iron overload. Liver Int. 2016 Oct;36(10):1540-8. doi: 10.1111/liv.13124. Epub 2016 Apr 6.</citation>
    <PMID>26998752</PMID>
  </reference>
  <reference>
    <citation>Gladine C, Newman JW, Durand T, Pedersen TL, Galano JM, Demougeot C, Berdeaux O, Pujos-Guillot E, Mazur A, Comte B. Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. PLoS One. 2014 Feb 18;9(2):e89393. doi: 10.1371/journal.pone.0089393. eCollection 2014.</citation>
    <PMID>24558496</PMID>
  </reference>
  <reference>
    <citation>Kim J, Carlson ME, Kuchel GA, Newman JW, Watkins BA. Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice. Int J Obes (Lond). 2016 Jan;40(1):129-37. doi: 10.1038/ijo.2015.135. Epub 2015 Jul 29.</citation>
    <PMID>26219414</PMID>
  </reference>
  <reference>
    <citation>Gouveia-Figueira S, Späth J, Zivkovic AM, Nording ML. Profiling the Oxylipin and Endocannabinoid Metabolome by UPLC-ESI-MS/MS in Human Plasma to Monitor Postprandial Inflammation. PLoS One. 2015 Jul 17;10(7):e0132042. doi: 10.1371/journal.pone.0132042. eCollection 2015.</citation>
    <PMID>26186333</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron absorption</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Dysmetabolic iron overload syndrome</keyword>
  <keyword>Metabolic syndrome X</keyword>
  <keyword>Genetic Hemochromatosis</keyword>
  <keyword>Oxylipin</keyword>
  <keyword>Lipidomic analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Hemochromatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

